Anti-Mouse IL-1b Antibody (B122)
Based on 1 Customer Validation
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure.
For research use only. We do not sell to patients.
- Purity : 99%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Armenian Hamster IgG
Recommend Isotype Controls
Species Reactivity
Mouse
|
IL-1 |
In Vitro
Anti-Mouse IL-1b Antibody (B122) (50 pM, 6-72 h) significantly inhibits the proliferation of various tumor cells combinated with Sulfasalazine (SAS), including SCC1, A375 and MDA-MB231 cells[1].
Anti-Mouse IL-1b Antibody (B122) (50 pM, 24 h) reduces the level of IL-1β and enhances the expression of ferroptosis markers combinated with SAS in SCC1 cells[1].
Anti-Mouse IL-1b Antibody (B122) (50 pM, 24 h) can increase the level of reactive oxygen species and decrease the level of GSH combinated with SAS in SCC1 cells[1].
Anti-Mouse IL-1b Antibody (B122) (50 pM) reverses T cell exhaustion and improves T cell function combinated with 40 % SAS conditioned medium[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SCC1, A375 and MDA-MB231 cells
-
Concentration:50 pM, combinated with SAS (800 μM)
-
Incubation Time:6, 12, 24, 48 and 72 h
-
Result:Significantly reduced the cell viability of three types of cells.
-
Cell Line:SCC1 cells
-
Concentration:50 pM, combinated with SAS (800 μM)
-
Incubation Time:24 h
-
Result:Reduced the level of PTSG2 and IL-1β and increased the level of SLC7A11.
-
Cell Line:SCC1 cells
-
Concentration:50 pM, combinated with SAS (800 μM)
-
Incubation Time:24 h
-
Result:Reduced the level of PTSG2 and IL-1β and increased the level of SLC7A11.
In Vivo
Anti-Mouse IL-1b Antibody (B122) (1 mg, intratumoral injection, once daily, until the endpoint) significantly prolongs the survival period in Ntv-a mice with PDGFB overexpression and p53 silencing[2].
Anti-Mouse IL-1b Antibody (B122) (100 μg, i.p., twice weekly, for 2 weeks) has a protective effect on right ventricular function and pulmonary vascular remodeling in C57BL/6J mice with a heart failure with preserved ejection fraction (HFpEF) model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nitrochin (HY-33354) (20 ppm) induced male Sprague-Dawley (SD) rats (4 weeks)[1]
-
Dosage:100 μg/kg, combined with SAS (30 mg/kg)
-
Administration:Intratumoral injection, once every 3 days for 4 weeks
-
Result:Caused only 16.6 % of cases to develop into mild invasive cancer, while 66.6 % of the control group had moderate invasive cancer.
Significantly inhibited tumor development with the lowest HE score.
Reduced the expression of SLC7A11 and IL-1β and increased the expression of PTGS2.
Reduced Ki67+ cells.
-
Animal Model:Ntv-a mice with a PDGFB glioblastoma (GBM) model(8-12 weeks)[2]
-
Dosage:1 mg
-
Administration:Intratumoral injection, once daily, until the endpoint
-
Result:Significantly prolonged the survival of PDGFB GBM mice (median survival extended from 40 days to 47 days).
Reduced tumor associated macrophage (TAMs) infiltration.
Reduced the expression of T cell exhaustion markers (such as PD-1).
-
Animal Model:L-NAME (HY-18729) (0.5 g/L) and high-fat diet (60 % lipid) administrated C57BL/6J mice (8 weeks)[3]
-
Dosage:100 μg
-
Administration:Intraperitoneal injection (i.p.), twice weekly, for 2 weeks
-
Result:Significantly reduced the level of IL-1β in lung tissue.
Reduced elevated right ventricular systolic pressure and pulmonary small vessel muscularization.
Had no significant effect on weight changes and right ventricular end diastolic pressure.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo IL-1β neutralization; in vitro IL-1β neutralization; ELISA
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse IL-1b Antibody (B122)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
-
Data Sheet (267 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Zhou R, et al. Sulfasalazine combined with anti-IL-1β mAb induces ferroptosis and immune modulation in oral squamous cell carcinoma. Cell Mol Life Sci. 2025 May 28;82(1):216. [Content Brief]
[2]. Chen Z, et al. A paracrine circuit of IL-1β/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression. J Clin Invest. 2023 Nov 15;133(22):e163802. [Content Brief]
[3]. Agrawal V, et al. Myeloid Cell Derived IL1β Contributes to Pulmonary Hypertension in HFpEF. Circ Res. 2023 Nov 10;133(11):885-898. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)